Photographer: Krisztian Bocsi/Bloomberg

Make Drugmakers Pay: England’s Strategy for Cancer Medicines

Updated on
  • Roche, Pfizer concerned new system has no spending limit
  • Fund reopens after four-month shutdown under NICE’s oversight

England is reopening its Cancer Drugs Fund with a crafty solution to rein in the overspending that blighted its predecessor: make drugmakers pay.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.